Daratumumab

Summary

Daratumumab (CHEMBL1743007) is an approved antibody (ATC L01FC01) targeting CD38; indicated across 46 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L01FC01
• Targets: 1 (CD38)
• Indications: 46 conditions
• Clinical trials: 314

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743007
Name	Daratumumab
Type	Antibody
Max phase	4
ATC	L01FC01

Also known as: Daratumumab, Daratumumab component of darzalex faspro, Daratumumab-fihj, Darzalex, HUMAX-CD 38, HUMAXCD38, HuMax-CD38, DARATUMUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD38	CD38	Antagonist	8.22	0%	P28907

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD38.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Metabolism	1	CD38
Nicotinate metabolism	1	CD38
Metabolism of water-soluble vitamins and cofactors	1	CD38
Metabolism of vitamins and cofactors	1	CD38

Dominant GO biological processes

GO term	Targets
response to hypoxia	1
signal transduction	1
positive regulation of cytosolic calcium ion concentration	1
female pregnancy	1
response to xenobiotic stimulus	1
negative regulation of neuron projection development	1
artery smooth muscle contraction	1
positive regulation of cell growth	1
positive regulation of B cell proliferation	1
positive regulation of insulin secretion	1
response to estradiol	1
response to retinoic acid	1
response to progesterone	1
response to hydroperoxide	1
B cell proliferation	1

Indications & clinical

Indications

46 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	4	MONDO:0009693	EFO:0001378
neoplasm	4	MONDO:0005070	EFO:0000616
amyloidosis	3	MONDO:0019065	EFO:1001875
smoldering plasma cell myeloma	3	MONDO:0005235	EFO:0003073
hereditary amyloidosis	3	MONDO:0018634	MONDO:0019438
lymphoma	2	MONDO:0005062	EFO:0000574
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
monoclonal gammopathy	2	MONDO:0004960	EFO:0000203
acute lymphoblastic leukemia	2	MONDO:0004967	EFO:0000220
acute myeloid leukemia	2	MONDO:0018874	EFO:0000222
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
colorectal carcinoma	2	MONDO:0024331	EFO:1001951
plasma cell leukemia	2	MONDO:0018689	EFO:0006475
Waldenstrom macroglobulinemia	2	MONDO:0100280	EFO:0009441
plasmacytoma	2	MONDO:0005615	EFO:0006738
autoimmune thrombocytopenic purpura	2	MONDO:0008558	EFO:0007160
POEMS syndrome	2	MONDO:0017364	EFO:1001115
follicular lymphoma	2	MONDO:0018906	MONDO:0018906
T-cell acute lymphoblastic leukemia	2	MONDO:0004963	EFO:0000209
lupus nephritis	2	MONDO:0005556	EFO:0005761
neuromyelitis optica	2	MONDO:0019100	EFO:0004256
Alzheimer disease	2	MONDO:0004975	MONDO:0004975
membranoproliferative glomerulonephritis	2	MONDO:0002461	MONDO:0018904
nephrotic syndrome	2	MONDO:0005377	EFO:0004255
glomerulonephritis	2	MONDO:0002462	MONDO:0002462
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915
leukemia	2	MONDO:0005059	EFO:0000565
lymphoid leukemia	2	MONDO:0005402	EFO:0004289
male reproductive organ cancer	2	MONDO:0005836	EFO:0007355
sickle cell disease	2	MONDO:0011382	MONDO:0011382
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
mycosis fungoides	1	MONDO:0009691	EFO:1001051
graft versus host disease	1	MONDO:0013730	EFO:0004599
glioblastoma	1	MONDO:0018177	EFO:0000519
non-autoimmune hemolytic anemia	1	MONDO:0021559	EFO:0005558
immune system disorder	1	MONDO:0005046	EFO:0000540
aplastic anemia	1	MONDO:0015909	HP:0001915
primary cutaneous T-cell non-Hodgkin lymphoma	1	MONDO:0000607	EFO:0002913
clear cell renal carcinoma	0	MONDO:0005005	EFO:0000349

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 314.

Phase distribution

Phase	Trials
PHASE2	142
PHASE1	52
PHASE3	50
PHASE1/PHASE2	37
Not specified	16
PHASE4	7
PHASE2/PHASE3	7
EARLY_PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03829371	PHASE4	ACTIVE_NOT_RECRUITING	STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
NCT05849740	PHASE4	RECRUITING	An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A
NCT05888870	PHASE4	RECRUITING	ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
NCT06409702	PHASE4	RECRUITING	Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT07274462	PHASE4	ACTIVE_NOT_RECRUITING	DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation)
NCT03768960	PHASE4	COMPLETED	A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
NCT05511428	PHASE4	COMPLETED	Home Based Daratumumab Administration for Patients With Multiple Myeloma
NCT03651128	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
NCT03652064	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
NCT03710603	PHASE3	ACTIVE_NOT_RECRUITING	Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma
NCT03742297	PHASE3	ACTIVE_NOT_RECRUITING	Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years
NCT03836014	PHASE3	ACTIVE_NOT_RECRUITING	Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
NCT03901963	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
NCT03937635	PHASE3	RECRUITING	Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT04071457	PHASE3	ACTIVE_NOT_RECRUITING	S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
NCT04181827	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04246047	PHASE3	ACTIVE_NOT_RECRUITING	Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04513639	PHASE2/PHASE3	RECRUITING	The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study
NCT04566328	PHASE3	RECRUITING	Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04975997	PHASE3	ACTIVE_NOT_RECRUITING	Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05020236	PHASE3	RECRUITING	A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05083169	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05257083	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05403138	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
NCT05438043	PHASE3	RECRUITING	A Study of Daratumumab
NCT05455320	PHASE3	ACTIVE_NOT_RECRUITING	A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05552222	PHASE3	RECRUITING	A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05561387	PHASE3	RECRUITING	Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05623020	PHASE3	RECRUITING	A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT06022939	PHASE3	RECRUITING	Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
NCT06182774	PHASE3	RECRUITING	Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
NCT06187441	PHASE3	RECRUITING	FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06296121	PHASE3	RECRUITING	A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
NCT06413498	PHASE3	RECRUITING	A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06464991	PHASE3	RECRUITING	A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
NCT06615479	PHASE3	RECRUITING	A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06679101	PHASE3	RECRUITING	A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06742138	PHASE3	NOT_YET_RECRUITING	To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
NCT06868654	PHASE3	ACTIVE_NOT_RECRUITING	China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT06868667	PHASE3	ACTIVE_NOT_RECRUITING	Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

3 molecules share ≥1 primary target. Top 3 by shared-target count:

Molecule	Source	Status	Shared targets
QUERCETIN	ChEMBL + PubChem	Phase 3 (approved)	CD38
LUTEOLIN	ChEMBL	Phase 2	CD38
Resveratrol	PubChem	Approved	CD38